Singapore’s Tourism Board And NATAS To Partner With The FinLab To Help Travel Agencies Evolve Through Digital Transformation

Source: https://www.opengovasia.com/articles/singapores-tourism-board-and-natas-to-partner-with-the-finlab-to-help-travel-agencies-evolve-through-digital-transformation

The Ministry of Communications and Information announced that The FinLab would be collaborating with the Singapore Tourism Board (STB) and the National Association of Travel Agents Singapore (NATAS) to help travel agencies evolve and renovate their businesses via a digital transformation programme for the selected businesses.

Singapore’s economy relies heavily on the tourism industry, which accounts for approximately four per cent of its annual gross domestic product. However, changing consumer behaviour and the growing competition for tourism dollars regionally pose a significant challenge to the industry.

Consequently, to ensure the industry’s continued growth, it is important for members of the industry to grasp the currently available opportunities in the online travel market, particularly those in the Asia Pacific online travel market, which is expected to grow by 13 per cent by focusing on technological transformation.

None the less, it was noted that despite most consumers moving to online booking sites, travel agencies retain the opportunity to go beyond the usual issuance of e-tickets and vouchers and, in addition to these services, provide consumers with more personalised services. Thus, travel agencies must understand how they can apply digital solutions to understand and connect more effectively with their target audience along with personal interaction.

In the face of a dynamic economic landscape in Singapore, travel agencies and the companies and initiatives that seek to help them grow and transform must remain constantly cognizant of the challenges that SMEs (small and medium-sized enterprises) face in harnessing the potential of technology and in transforming it into benefits for their businesses.

Experts maintain that in order for the travel industry to continue to capitalise on growth opportunities in the long-term it must continue to innovate. One avenue to do this is to collaborate with partners who have the expertise to assist Singapore’s travel agents in developing digital competencies.

The FinLab, a partnership between SGInnovate and United Overseas Bank (UOB), is a business accelerator formed to propel technology companies and catalyse the digital transformation of businesses.

The FinLab’s programme presents the selected Singaporean travel agencies the opportunity to not only connect to The Finlab’s ecosystem of associates to transform their business digitally but also enables them to use what they have learned to improve their business’ performance, enhance consumer experiences and seize business opportunities present in the digital economy.

Ms Ong Ling Lee, Director at Travel Agents and Tourist Guides, STB stated that their collaboration with The FinLab is one of several initiatives created to support travel agencies and help them grown and transform their businesses in an increasingly competitive tourism market. “We hope that with the practical guidance provided by this acceleration programme, travel agents will be encouraged to take the first step towards achieving their growth ambitions”, Ms Lee added.

Advertisements

Advanced Oncotherapy (AVO) Selects RayStation for the First LIGHT System in Central London

Source: https://www.prnewswire.com/news-releases/advanced-oncotherapy-avo-selects-raystation-for-the-first-light-system-in-central-london-300676566.html

The UK based developer of next generation proton therapy technology, Advanced Oncotherapy plc (AVO), has selected RayStation as its treatment planning system for the first LIGHT (Linac Image Guided Hadron Technology) system at the proton therapy facility under construction at Harley Street in central London. Users at the clinic will have access to the full spectrum of RayStation’s functionality.

AVO and RaySearch have entered into a collaboration agreement to support the LIGHT system fully. The LIGHT system is a modular proton therapy system based on innovative technology, developed in a collaboration between the TERA project and CERN in Geneva, Switzerland. The heart of the system consists of a treatment room integrated with a linear accelerator, which accelerates protons to energies suitable for radiation therapy of cancer. The entire system is designed for cost effectiveness and low maintenance and has several key features, such as multiple spot sizes and fast energy switching time.

The order of RayStation for Harley street gives the users access to the full spectrum of RayStation’s functionality, including the fast proton Monte Carlo dose engine, robust 4D optimization, LET driven optimization, deformable registration, dose accumulation, plan adaptation, multi-criteria optimization and Plan Explorer for automatic plan generation.

Nicolas Serandour, AVO Chief Executive Officer, says: “We are thrilled to collaborate with RaySearch. RaySearch has established themselves as the technology of choice for light ion therapy treatment planning. As we bring our advanced particle therapy treatment technology into the field, it makes sense to have the most advanced treatment planning capability to complement it. We believe the synergetic combination is significant for optimizing patient care at our first proton therapy center in the renowned medical practice area of Harley Street, London.”

Travel suppliers eye India’s outbound tourism market

Source: http://thehitavada.com/Encyc/2018/6/3/Travel-suppliers-eye-India-s-outbound-tourism-market.aspx

TRAVEL and tourism businesses around the world are looking to capitalise on India’s double-digit annual growth in the outbound MICE and luxury travel segment, with the value of India’s business travel market expected to reach USD 93 billion by 2030, organisers of an industry event have said.
India has recently moved up two places to become the eighth largest business travel market in the world, and business travel spending in the country is projected to record a compound annual growth rate of 12 per cent through 2020, they said.
As India maintains its double-digit annual growth in the outbound meetings, incentives, conferences and exhibitions (MICE) and luxury travel segment, travel and tourism businesses around the world are looking to capitalise on the country’s growth potential.
The MICE market refers to a niche of group tourism dedicated for planning, booking, and facilitating conferences, seminars, and other events.
Forging business opportunities and partnerships with leading Indian corporates and luxury travel specialists will be discussed at the 6th annual MICE India and Luxury Travel (MILT) Congress, the premier B2B event that caters to both the business travel and luxury tourism sectors in India.
Organised by Dubai-based QnA International, the MILT Congress will be held this year in Mumbai from July 25-26 and in Delhi from July 31-August 01.
By 2030, the value of India’s business travel market is expected to reach USD 93 billion, a statement released here said.
Noting that Indian corporates remain largely unaffected by the global slowdown and continue to spend big on corporate travel, Hassan Madah, Director, Israel Ministry of Tourism – India and the Philippines, said.
India is among the largest source markets for MICE tourism in both Dubai and Abu Dhabi, and the travel and hospitality companies in both the Emirates are looking to further expand their reach in the Indian market by taking advantage of the unique networking opportunities provided by MILT Congress 2018 with its high-profile buyer lineup.
The United Nations World Tourism Organisation (UNWTO), meanwhile, has forecast that India will account for 50 million outbound tourists by 2020.
Business and luxury travel is expected to make up a significant share of the total volume of outbound travel, with one report indicating the country is on track to generating 6.5 million outbound luxury and MICE tourists annually by 2020.
Ackash Jain, Director, QnA International, said, “India has been maintaining an annual GDP growth rate of 6-8 per cent since 2013, and this strong economic momentum is rubbing off on the country’s outbound MICE and luxury travel sector, enabling these segments to post a double digit year- on-year growth”.
According to Jain, the rise of incentive travel, which has emerged as one of the fastest growing segments within India’s outbound business travel
market, is opening a new dimension of opportunities for travel and hospitality suppliers around the world.

China In Vitro Diagnostic Market Promising development scope 2025

China in vitro diagnostics(IVD) market is anticipated to grow over US$ 11 Billion by 2025 with an impressive double-digit growth rate in the forecast period 2018 – 2025.
The market is driven by number of factors such as rising incidences of chronic lifestyle diseases, public health awareness, demand of tests in rural areas stimulated by the healthcare reform plan, increasing demand from the middle class for high–end products and an increase in the number of private hospitals and independent testing laboratories.
“China In Vitro Diagnostics (IVD) Market Analysis 2012 – 2017 and Forecast 2018 – 2025: Clinical Chemistry, Immunoassay, Molecular Testing, SMBG, Point of Care Testing (POCT), Hematology, Coagulation, Microbiology, Genetic Testing, Infectious Diagnostics, Histology and Cytology” presents an in-depth assessment of the in vitro diagnostics(IVD) market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for in vitro diagnostics(IVD) in China. The research includes historic data from 2012 to 2017 and forecasts until 2025.
The report contains a granular analysis of the China in vitro diagnostics market segmentation by 11 applications and illustrative forecast to 2025. A comprehensive analysis has been done on market share of China in vitro diagnostics by application, end-user and company share by revenue.
The report also includes assessment of in vitro diagnostics regulation in China. Key trends in terms of partnerships and recent developments are analyzed with details. The report also explores detailed description of growth drivers, restraints, trends and opportunities of the China in vitro diagnostics market.
Market Segmentation by Application and Analysis (2012 – 2025)
•Clinical Chemistry
• Immunoassay
•Molecular Testing
• Self–Monitoring of Blood Glucose (SMBG)
•Point of Care Testing (POCT)
•Hematology
•Coagulation
•Microbiology
• Genetic Testing
• Infectious Diagnostics
• Histology and Cytology
The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:
• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Sysmex Corporation
• Mindray Medical International Limited
• Beckman Coulter Inc
• Shanghai Fosun Pharmaceutical Group
• Thermo Fisher Scientific Inc
• Hologic Inc
• Qiagen
• Cepheid
• Bio-Rad Laboratories Inc
• Da An Gene Co. Ltd
• Shanghai Kehua Bio–Engineering Co. Ltd.
The Latest Industry Data Included in this Report:
• China In Vitro Diagnostics Market Revenue & Forecast (2012 – 2025)
• China In Vitro Diagnostics Market Dynamics
• China In Vitro Diagnostics Market Segmentation by Application (2012 – 2025)
• China In Vitro Diagnostics Market Revenue Share by Application (2012 – 2025)
• China In Vitro Diagnostics Market, Company Share by Revenue, 2017
• China In Vitro Diagnostics Market Share by End-User (Hospitals, Homecare, Research Institutes, Independent laboratories),2017
• Assessment of In Vitro Diagnostics Regulation in China
• Major Partnership Deals in China In Vitro Diagnostics Market
• Recent Developments in China In Vitro Diagnostics Market
• Overview of Key Companies in China In Vitro Diagnostics Market

Reimbursement for NIPT test will revolutionize the market in the Forecast

Global Non-Invasive Prenatal Testing(NIPT) market is anticipated to grow over US$ 2.5 Billion by 2025 with an impressive double-digit growth rate in the forecast period 2018 – 2025. 
The market is driven by number of factors such as high incidence rate of babies born with down syndrome, no risk of miscarriage with NIPT test, shifting trend towards child bearing at advanced maternal age (35 years or older), rising focus on reimbursement for NIPT and increasing preference for non-invasive techniques over invasive methods.
“Global Non-Invasive Prenatal Testing Market: Demand, Insights, Analysis, Opportunities, Growth Potential and Forecast 2018 – 2025” presents an in-depth assessment of the Global Non-Invasive Prenatal Testing (NIPT) market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for Global Non-Invasive Prenatal Testing (NIPT). The research includes historic data from 2014 to 2017 and forecasts until 2025.
The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, NIPT test volume, revenues and provides forecasts through 2025. A comprehensive analysis has been done on market share of NIPT tests and Countries-based market. The report also includes assessment of comparative test analysis by companies. Additionally, the report includes insights into the Global perspectives on clinical adoption of NIPT. Key trends in terms of collaboration, partnership, merger & acquisition, venture capital investment, distribution and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Non-Invasive Prenatal Testing (NIPT) market.
The report concludes with the profiles of major players in the Global Non-Invasive Prenatal Testing (NIPT) market. The key market players are evaluated on various parameters such as company overview, NIPT test portfolios and latest development and trends of the Non-Invasive Prenatal Testing (NIPT) market.
Key Findings:
• United States is anticipated to be the most attractive market in the Global Non-Invasive Prenatal Testing(NIPT) market
• China NIPT test market is set to cross USD 400 Million by 2025
• Panorama test accounted for the highest share in Global Non-Invasive Prenatal Testing(NIPT) market
• Verifi test has the second highest revenue share in the Global Non-Invasive Prenatal Testing(NIPT) market
• Rising focus on Reimbursement for NIPT test will revolutionize the market
• Two–Child policy is likely to boost China NIPT market
The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:
 
Illumina, Natera, Sequenom Laboratories (LabCorp), Ariosa Diagnostics (Roche), BGI Diagnosis Co. Ltd, Berry Genomics, Quest Diagnostics, LifeCodexx AG, Premaitha Health, NIPD Genetics
Major and Promising Non-Invasive Prenatal Testing (NIPT) Covered Under This Report are:
Panorama, MaterniT21 PLUS, Harmony, Verifi, NIFTY, IONA, PrenaTest, Bambni, Veracity and Other Tests
Major Countries Analyzed Under This Report are:
United States, China, Japan, India, Brazil, Australia, New Zealand, United Kingdom, Germany, Italy, Spain, France, Switzerland, Sweden, Belgium, Russia, Turkey, Netherland, Poland, Armenia, Moldova, Denmark and Rest of the Countries.
The Latest Industry Data Included in this Report:
• Global Non–Invasive Prenatal Testing Market Volume & Future Trends (2014 – 2025)
• Global Non–Invasive Prenatal Testing Market Revenue & Future Trends (2014 – 2025)
• Global Non–Invasive Prenatal Testing Market Share and Y–o–Y Growth (%)
• Market Share Analysis, by Test, 2014 – 2025 (%)
• Market Share Analysis, by Major Countries, 2014 – 2025 (%)
• Global Non–Invasive Prenatal Testing Market, By Test (Volume and Value),2011 – 2025
• Global Non–Invasive Prenatal Testing Market, By Geography (Volume and Value),2014 – 2025
• Non–Invasive Prenatal Testing(NIPT) Comparative Analysis – By Test
• Major Deals in Global Non–Invasive Prenatal Testing Market
• Global Perspectives on Clinical Adoption of NIPT
• Global Non–Invasive Prenatal Testing Market Drivers and Inhibitors
• Key Companies Analysis

Thailand tops MICE scene

Source: http://www.nationmultimedia.com/detail/Tourism/30347051

THAILAND has been rated the top destination for the meetings, incentive travel, convention and exhibition (MICE) sector, according to a survey released by the Thailand Convention and Exhibition Bureau (TCEB).

According to the survey, Thailand secured the top spot with the so-called delight factors in hospitality, value for money, good variety of international and local cuisine and MICE activities. The poll was conducted by Custom Asia Co Ltd to survey and sought responses about the preferred destinations for business travel and MICE trips.

The TCEB also announced that Thailand was chosen as the host country for international conferences organised by the world’s leading associations in events and travel incentive industries, UFI and SITE. These events, which will take place in Bangkok next year, will be emphasise Thailand’s potential and its position as the leading MICE destination in the region.

TCEB president Chiruit Isarangkun Na Ayuthaya said that TCEB is tasked with promoting and developing business events in Thailand. The bureau has been working toward establishing Thailand as premier MICE destination and elevating the country to be the “Top of Mind Destination for MICE”.

In order to identify the strengthens of Thailand to better attract the overseas MICE markets, the TCEB needs to study key factors that influence the destination choice, evaluate Thailand MICE destination image, and measure the competitiveness of Thailand when compared to other MICE destinations.

Visit for More Reports on MICE Tourism: http://www.dpiresearch.com/

United States Pediatric Vacccine Market Size by Top Key Players Like Sanofi Pasteur, GlaxoSmithKline(GSK), Merck & Co., Pfizer Inc and Grifols 2018 – 2025

United States pediatric vaccines market is expected to grow over US$ 15 Billion by 2025, driven by increased disease awareness, growing public acceptance, increasing government focus on immunization programs and increased government funding for the vaccines development.
“Pediatric Vaccines Market: United States Industry Analysis, Trends, Opportunity, Market Size and Segment Forecasts, 2018 – 2025” provides a unique tool for evaluating the market, highlighting opportunities, supporting strategic and tactical decision–making. This report recognizes that in this rapidly–evolving and competitive environment, up–to–date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments and focuses on United States pediatric vaccines market. The report also provides clear insight into current and future developments of the United States pediatric vaccines market. Furthermore, this report provides a deep and thorough evaluation of the top 10 pediatric vaccines by disease indication. On the basis of disease indication, the top 10 pediatric vaccines provide an in-depth analysis of doses administered, number of children being vaccinated and market size. The research includes historic data from 2010 to 2017 and forecasts until 2025.
The report also explores detailed description of growth drivers and inhibitors of the United States pediatric vaccines market.
The report concludes with the profiles of major players in the United States pediatric vaccines market. The key market players are evaluated on various parameters such as company overview, pediatric vaccines portfolios and latest development & trends of the pediatric vaccines market.
The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:
• Sanofi Pasteur
• GlaxoSmithKline(GSK)
• Merck & Co.
• Pfizer Inc
• Grifols
Major Pediatric Vaccines (Disease Indication) Covered Under This Report Are:
• Diphtheria, Tetanus & Pertussis (DTap)
• Hepatitis A
• Varicella/Chicken Pox
• Pneumococcal
• Haemophilus Influenzae Type B (HIB)
• Polio
• Rotavirus
• Hepatitis B
• Influenza Pediatric
• Measles, Mumps & Rubella (MMR)
The Latest Industry Data Included in this Report:
• United States Pediatric Vaccines Market Size & Analysis ,2010 – 2025
• United States Pediatric Vaccines Market Share and Y–o–Y Growth (%),2010 – 2025
• United States Pediatric Vaccines Market by Disease Indication ,2010 – 2025
• 10 Pediatric Vaccines Doses Administered (Volume),2010 – 2025
• Number of Children Being Vaccinated (Volume)2010 – 2025
• 10 Pediatric Vaccines Market Size and Forecast(Value),2010 – 2025
• Key Market Drivers and Inhibitors of the United States Pediatric Vaccines Market
• A Comprehensive List of Key Market Players Along with the Analysis of their Current
   Product Portfolios and Latest Recent Development and Trends
The Following Key Questions have been Addressed in the Report:
• What is the size of the United States pediatric vaccines market during 2010 -2025?
• How will each segment of the United States pediatric vaccines market grow
   during the forecast period and what will be the revenue generated
   by each of the segments by the end of 2025?
• Which major pediatric vaccines provides highest market share?
• How much number of children being vaccinated during 2010 – 2025?
• How are the overall market and segments types growing?
• What are the major market drivers and inhibitors in the United States pediatric vaccines market?
• Who are the key players in the United States pediatric vaccines market and
   what are their contributions?